CP-x Synthetic Cannabinoids Research Dashboard
Double-blind human trials
Clinical human trials
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 44 studies associated with CP-x Synthetic Cannabinoids.
Here is a small sampling of CP-x Synthetic Cannabinoids studies by title:
- Chronic Adolescent Δ9-Tetrahydrocannabinol Treatment of Male Mice Leads to Long-Term Cognitive and Behavioral Dysfunction, Which Are Prevented by Concurrent Cannabidiol Treatment
- Cannabinoid receptor-specific mechanisms to alleviate pain in sickle cell anemia via inhibition of mast cell activation and neurogenic inflammation.
- Selective Cannabinoid Receptor-1 Agonists Regulate Mast Cell Activation in an Oxazolone-Induced Atopic Dermatitis Model.
- Comparing the effects of endogenous and synthetic cannabinoid receptor agonists on survival of gastric cancer cells.
- Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease.
Components of the CP-x Synthetic Cannabinoids Research Dashboard
- Top medical conditions associated with CP-x Synthetic Cannabinoids
- Proven effects in clinical trials for CP-x Synthetic Cannabinoids
- Receptors associated with CP-x Synthetic Cannabinoids
- Individual study details for CP-x Synthetic Cannabinoids
Ready to become a subscriber? Go to our PRICING page.
Members can filter by the following criteria:
- Study Type
- Organ Systems
- Study Result
- Year of Publication
Overview - CP-x Synthetic Cannabinoids
Description of CP-x Synthetic Cannabinoids
The CP class of synthetic cannabinoids are named after the company Carl Pfizer where they were first synthesized. For instance, CP-55,940 was discovered in 1974.
CP Family Synthetic Cannabinoids
CP-x Synthetic Cannabinoids Properties and Effects
Binds with PPAR-Gamma and initiates anti-inflammatory response, Binds with GPR55
CP-x Synthetic Cannabinoids Receptor Binding
Strong affinity for CB1 with a mean Kd at 2.5nM (10 times more potent than THC). Very strong affinity for CB2 with a mean Kd at 0.92nM (38 times more potent than THC)
Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.